Drotrecogin alfa

DB00055

biotech approved investigational withdrawn

Deskripsi

Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective in improving outcomes in patients with sepsis.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 5.5 hours (mammalian reticulocytes, in vitro).
Volume Distribusi -
Klirens (Clearance) * 40 L/hr [severe sepsis adults] * 30 +/- 8 L/hr [patients without sepsis undergoing hemodialysis] * 28 +/- 9 L/hr [heathy]

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.

Interaksi Obat

641 Data
Apixaban Apixaban may increase the anticoagulant activities of Drotrecogin alfa.
Dabigatran etexilate Dabigatran etexilate may increase the anticoagulant activities of Drotrecogin alfa.
Dasatinib The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Drotrecogin alfa.
Deferasirox The risk or severity of gastrointestinal bleeding can be increased when Drotrecogin alfa is combined with Deferasirox.
Ursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Ursodeoxycholic acid.
Glycochenodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Glycochenodeoxycholic Acid.
Cholic Acid The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Cholic Acid.
Glycocholic acid The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Glycocholic acid.
Deoxycholic acid The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Deoxycholic acid.
Taurocholic acid The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Taurocholic acid.
Obeticholic acid The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Obeticholic acid.
Chenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Chenodeoxycholic acid.
Taurochenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Taurochenodeoxycholic acid.
Tauroursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Tauroursodeoxycholic acid.
Bamet-UD2 The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Bamet-UD2.
Dehydrocholic acid The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Dehydrocholic acid.
Hyodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Hyodeoxycholic Acid.
Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Drotrecogin alfa.
Ibrutinib The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Drotrecogin alfa.
Obinutuzumab The risk or severity of bleeding and hemorrhage can be increased when Drotrecogin alfa is combined with Obinutuzumab.
Rivaroxaban Drotrecogin alfa may increase the anticoagulant activities of Rivaroxaban.
Sugammadex The risk or severity of bleeding and hemorrhage can be increased when Drotrecogin alfa is combined with Sugammadex.
Tibolone Tibolone may increase the anticoagulant activities of Drotrecogin alfa.
Tipranavir The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Drotrecogin alfa.
Urokinase Urokinase may increase the anticoagulant activities of Drotrecogin alfa.
Vitamin E Vitamin E may increase the anticoagulant activities of Drotrecogin alfa.
Vorapaxar The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Drotrecogin alfa.
Aprotinin The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Aprotinin.
Ginkgo biloba Ginkgo biloba may increase the anticoagulant activities of Drotrecogin alfa.
Ifosfamide The risk or severity of bleeding can be increased when Ifosfamide is combined with Drotrecogin alfa.
Quinine The therapeutic efficacy of Drotrecogin alfa can be increased when used in combination with Quinine.
Quinidine The therapeutic efficacy of Drotrecogin alfa can be increased when used in combination with Quinidine.
Tamoxifen The risk or severity of bleeding can be increased when Tamoxifen is combined with Drotrecogin alfa.
Toremifene The risk or severity of bleeding can be increased when Toremifene is combined with Drotrecogin alfa.
Pentoxifylline The therapeutic efficacy of Drotrecogin alfa can be increased when used in combination with Pentoxifylline.
Pentosan polysulfate Pentosan polysulfate may increase the anticoagulant activities of Drotrecogin alfa.
Levocarnitine The therapeutic efficacy of Drotrecogin alfa can be increased when used in combination with Levocarnitine.
Diethylstilbestrol Diethylstilbestrol may decrease the anticoagulant activities of Drotrecogin alfa.
Chlorotrianisene Chlorotrianisene may decrease the anticoagulant activities of Drotrecogin alfa.
Conjugated estrogens Conjugated estrogens may decrease the anticoagulant activities of Drotrecogin alfa.
Mestranol The risk or severity of adverse effects can be increased when Mestranol is combined with Drotrecogin alfa.
Estrone sulfate Estrone sulfate may decrease the anticoagulant activities of Drotrecogin alfa.
Quinestrol Quinestrol may decrease the anticoagulant activities of Drotrecogin alfa.
Hexestrol Hexestrol may decrease the anticoagulant activities of Drotrecogin alfa.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Drotrecogin alfa.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Drotrecogin alfa.
Polyestradiol phosphate Polyestradiol phosphate may decrease the anticoagulant activities of Drotrecogin alfa.
Esterified estrogens Esterified estrogens may decrease the anticoagulant activities of Drotrecogin alfa.
Zeranol Zeranol may decrease the anticoagulant activities of Drotrecogin alfa.
Equol Equol may decrease the anticoagulant activities of Drotrecogin alfa.
Methallenestril Methallenestril may decrease the anticoagulant activities of Drotrecogin alfa.
Epimestrol Epimestrol may decrease the anticoagulant activities of Drotrecogin alfa.
Moxestrol Moxestrol may decrease the anticoagulant activities of Drotrecogin alfa.
Estradiol acetate Estradiol acetate may decrease the anticoagulant activities of Drotrecogin alfa.
Estradiol benzoate Estradiol benzoate may decrease the anticoagulant activities of Drotrecogin alfa.
Estradiol cypionate Estradiol cypionate may decrease the anticoagulant activities of Drotrecogin alfa.
Estradiol valerate Estradiol valerate may decrease the anticoagulant activities of Drotrecogin alfa.
Biochanin A Biochanin A may decrease the anticoagulant activities of Drotrecogin alfa.
Formononetin Formononetin may decrease the anticoagulant activities of Drotrecogin alfa.
Estriol Estriol may decrease the anticoagulant activities of Drotrecogin alfa.
Icosapent The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Drotrecogin alfa.
Mesalazine The risk or severity of bleeding can be increased when Mesalazine is combined with Drotrecogin alfa.
Indomethacin The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Drotrecogin alfa.
Nabumetone The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Drotrecogin alfa.
Ketorolac The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Drotrecogin alfa.
Tenoxicam The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Drotrecogin alfa.
Celecoxib The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Drotrecogin alfa.
Tolmetin The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Drotrecogin alfa.
Rofecoxib The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Drotrecogin alfa.
Piroxicam The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Drotrecogin alfa.
Fenoprofen The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Drotrecogin alfa.
Valdecoxib The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Drotrecogin alfa.
Diclofenac The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Drotrecogin alfa.
Sulindac The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Drotrecogin alfa.
Flurbiprofen The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Drotrecogin alfa.
Etodolac The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Drotrecogin alfa.
Mefenamic acid The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Drotrecogin alfa.
Naproxen The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Drotrecogin alfa.
Sulfasalazine The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Drotrecogin alfa.
Phenylbutazone The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Drotrecogin alfa.
Meloxicam The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Drotrecogin alfa.
Carprofen The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Drotrecogin alfa.
Diflunisal The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Drotrecogin alfa.
Salicylic acid The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Drotrecogin alfa.
Meclofenamic acid The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Drotrecogin alfa.
Oxaprozin The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Drotrecogin alfa.
Ketoprofen The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Drotrecogin alfa.
Balsalazide The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Drotrecogin alfa.
Olsalazine The risk or severity of bleeding can be increased when Olsalazine is combined with Drotrecogin alfa.
Lumiracoxib The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Drotrecogin alfa.
Magnesium salicylate The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Drotrecogin alfa.
Salsalate The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Drotrecogin alfa.
Choline magnesium trisalicylate The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Drotrecogin alfa.
Antrafenine The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Drotrecogin alfa.
Aminophenazone The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Drotrecogin alfa.
Antipyrine The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Drotrecogin alfa.
Tiaprofenic acid The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Drotrecogin alfa.
Etoricoxib The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Drotrecogin alfa.
Taxifolin The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Drotrecogin alfa.
Oxyphenbutazone The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Drotrecogin alfa.

Target Protein

Coagulation factor VIII F8
Coagulation factor V F5
Plasminogen activator inhibitor 1 SERPINE1
Thrombomodulin THBD
Vitamin K-dependent protein S PROS1
Prothrombin F2
Platelet factor 4 PF4
Plasma serine protease inhibitor SERPINA5
Serpin B6 SERPINB6
Endothelial protein C receptor PROCR

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 6 • International brands: 0
Produk
  • Xigris
    Injection, powder, lyophilized, for solution • 5 mg/2.5mL • Intravenous • US • Approved
  • Xigris
    Injection, powder, lyophilized, for solution • 20 mg/10mL • Intravenous • US • Approved
  • Xigris
    Injection, powder, for solution • 5 mg • Intravenous • EU
  • Xigris
    Injection, powder, for solution • 20 mg • Intravenous • EU
  • Xigris (20mg/vial)
    Powder, for solution • 20 mg / vial • Intravenous • Canada • Approved
  • Xigris (5mg/vial)
    Powder, for solution • 5 mg / vial • Intravenous • Canada • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul